ASP Isotopes adds Renergen leaders to executive team

ASP Isotopes Inc. reported leadership changes tied to its closing of the previously announced acquisition of Renergen Limited on January 6, 2026.

Rhea-AI Filing Summary

ASP Isotopes Inc. reported leadership changes tied to its closing of the previously announced acquisition of Renergen Limited on January 6, 2026. Renergen’s Chief Executive Officer, Stefano Marani, has been appointed President, Electronics and Space of ASP Isotopes, and Renergen’s Chief Operating Officer, Nick Mitchell, has been appointed Co-Chief Operating Officer of ASP Isotopes.

The company expects to enter into employment agreements providing Mr. Marani a base salary of $550,000 per year and Mr. Mitchell $400,000 per year, each with a target annual discretionary bonus equal to 50% of base salary, payable in a mix of cash and common stock. Each executive has been approved for a grant of 700,000 shares of common stock, vesting in eight equal installments over four years, with 87,500 shares vesting on each six‑month anniversary of employment, subject to continued service.

The stock awards are being made under ASP Isotopes’ inducement equity incentive plans in line with Nasdaq Listing Rule 5635(c)(4), and both executives will also be eligible for annual equity awards under the company’s 2022 Equity Incentive Plan. Due to prior transactions between ASP Isotopes and Renergen, including a $30 million bridge loan agreement, the company notes that Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest in such dealings for related‑party disclosure purposes.

Insights

Corporate governance and M&A integration analyst

ASP Isotopes brings Renergen leadership in-house with equity-heavy pay tied to its recent acquisition.

ASP Isotopes is formalizing post-acquisition integration by appointing Renergen’s leaders, Stefano Marani and Nick Mitchell, into senior roles at the combined company. This aligns operational leadership of the acquired Virginia Gas Project and related activities with ASP Isotopes’ structure, potentially smoothing integration because both executives have long tenures and project-specific experience at Renergen.

The planned compensation packages combine substantial cash salaries of $550,000 and $400,000 with target bonuses at 50% of base salary and sizeable equity inducements of 700,000 shares each. The four-year, semiannual vesting schedule encourages retention and aligns incentives with long-term company performance, while inducement plan usage follows Nasdaq Listing Rule 5635(c)(4). The prior $30 million bridge loan and other Renergen transactions mean the executives may be deemed to have a material interest in these dealings, which the company highlights under related-party disclosure rules.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive changes did ASP Isotopes Inc. (ASPI) disclose in this 8-K?

ASP Isotopes appointed Renergen CEO Stefano Marani as President, Electronics and Space, and Renergen COO Nick Mitchell as Co-Chief Operating Officer following the closing of its acquisition of Renergen on January 6, 2026.

What are the base salaries and bonus targets for Stefano Marani and Nick Mitchell at ASP Isotopes (ASPI)?

ASP Isotopes expects to pay Stefano Marani a base salary of $550,000 per year and Nick Mitchell $400,000 per year, each with a target annual discretionary bonus equal to 50% of base salary, payable in a mix of cash and common stock.

What equity awards are being granted to the new ASP Isotopes executives from Renergen?

The compensation committee approved grants of 700,000 shares of common stock to each of Mr. Marani and Mr. Mitchell. These restricted shares vest in eight equal installments over four years, with 87,500 shares vesting on each six-month employment anniversary, subject to continued employment.

Under which plans are the inducement equity awards to ASP Isotopes’ new executives being made?

The restricted stock awards to Mr. Marani and Mr. Mitchell are being made under ASP Isotopes’ 2024 Inducement Equity Incentive Plan and 2025 Inducement Equity Incentive Plan as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). They are also eligible for annual awards under the 2022 Equity Incentive Plan.

How are ASP Isotopes (ASPI) and Renergen financially connected according to the filing?

The filing notes prior transactions between ASP Isotopes and Renergen, including a $30 million bridge loan agreement dated May 19, 2025, with ASP Isotopes South Africa Proprietary Limited as lender and Renergen as borrower. Because of these dealings, Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest under Item 404(a) of Regulation S-K.

Will ASP Isotopes file more details on the employment agreements with the new executives?

Yes. The company states it expects to enter into employment agreements with Mr. Marani and Mr. Mitchell and will file an amendment to this report within four business days after the terms are finalized to provide any additional information required by Item 5.02.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 05:00 PM Learn about SEC filing dates

0001921865false00019218652026-01-062026-01-06iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2026

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41555		87-2618235
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2200 Ross Avenue, Suite 4575E Dallas, TX		75201
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (214) 432-8219

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		ASPI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 7, 2026, ASP Isotopes Inc. (the “Company”) announced that in connection with the closing of the Company’s previously announced acquisition of Renergen Limited (“Renergen”), on January 6, 2026 (the “Closing Date”), Stefano Marani, the Chief Executive Officer of Renergen, was appointed as the President, Electronics and Space, of the Company, and Nick Mitchell, the Chief Operating Officer of Renergen, was appointed Co-Chief Operating Officer of the Company.

Mr. Marani, age 48, has served as the Chief Executive Officer of Renergen and a member of the Board of Directors of Renergen since November 2014.  As co-founder of Renergen, Mr. Marani is responsible for managing Renergen’s overall operations, including the execution of the Virginia Gas Project. Mr. Marani was part of the team which acquired the Gas Fields from Molopo Energy Limited in April 2013 and was instrumental in taking the Gas Fields from a stranded gas asset into production with funding from the United States government. Mr. Marani has significant experience in the areas of structured finance and advisory, having previously worked at Deutsche Bank and Morgan Stanley. Mr. Marani holds a BSc in Actual Science and a BSc (Hons) in Advance Mathematics of Finance from the University of Witwatersrand.

Mr. Mitchell, age 46, has served as Chief Operating Officer and a member of the Board of Directors of Renergen since November 2015. In this capacity, he drives Renergen’s strategic direction and oversees all operational activities, including the flagship Virginia Gas Project. Since March 2017, Mr. Mitchell has chaired the Oil and Natural Gas Producers Association of South Africa (ONPASA), and he has been a Trustee of the South African Oil and Gas industries Upstream Training Trust (UTT) since December 2020, thereby contributing to industry leadership, policy development and youth skills and knowledge development. His entrepreneurial vision was instrumental in transforming Tetra4 from a stranded gas asset into a world-class helium and natural gas reserve following its acquisition in 2013. Mr. Mitchell brings extensive expertise in operations management, commercial development, and strategic risk management. Mr. Mitchell qualified as a Microsoft Certified Systems Engineer and was also A+ Certified.

The Company expects to enter into an employment agreement with Mr. Marani providing for a base salary of $550,000 per annum (subject to annual adjustments by the board of directors) and a target annual discretionary bonus equal to 50% of his annual base salary. The Company expects to enter into an employment agreement with Mr. Mitchell providing for a base salary of $400,000 per annum (subject to annual adjustments by the board of directors) and a target annual discretionary bonus equal to 50% of his annual base salary.  Annual bonuses will be paid in a mixture of cash and common stock, as determined by the compensation committee.  Once the terms of such employment agreements are finalized, the Company will file an amendment to this Current Report on Form 8-K to report any additional information required by Item 5.02 of Form 8-K within four business days after such information is determined or becomes available.

As previously disclosed, in connection with the closing of the acquisition of Renergen, the Company’s Compensation Committee approved the grant to each of Messrs. Marani and Mitchell 700,000 shares of the Company’s common stock.  Subject to each recipient being continuously employed by the Company through each applicable vesting date, the shares will vest in eight equal instalments over four years, with 87,500 shares vesting on each of the six-month anniversaries of each recipient’s employment start date.  The restricted stock awards are made pursuant to the Company’s 2024 Inducement Equity Incentive Plan and the Company’s 2025 Inducement Equity Incentive Plan as an inducement material to each recipient entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4), and will be subject to the terms and conditions of the applicable award agreements to be entered into between the Company and each recipient thereof.  Messrs. Marani and Mitchell will also be eligible to receive annual equity-based awards pursuant to the Company’s 2022 Equity Incentive Plan.

Messrs. Marani and Mitchell will also enter into the Company’s standard form of indemnification agreement, a copy of which has been incorporated by reference as Exhibit 10.4 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2025.

Except as previously disclosed by the Company in its Form 8-K filed on May 20, 2025, there are no arrangements or understandings between Mr. Marani or Mr. Mitchell and any other person pursuant to which either Mr. Marani or Mr. Mitchell was selected as an officer of the Company. There are no family relationships between Mr. Marani or Mr. Mitchell and any of the executive officers or directors of the Company. There is no information that is required to be disclosed with respect to Mr. Marani or Mr. Mitchell pursuant to Item 404(a) of Regulation S-K, except for the transactions between the Company and Renergen that have been previously disclosed by the Company, including the $30 million bridge loan agreement, dated May 19, 2025, by and among the Company, ASP Isotopes South Africa Proprietary Limited, as lender, and Renergen, as borrower, as disclosed by the Company in its Form 8-K filed on May 20, 2025 and subsequent SEC filings.  As a result of such financial relationship between the Company and Renergen, Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest with respect to the Company’s transactions with Renergen as contemplated by Item 404(a) of Regulation S-K.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASP ISOTOPES INC.
Date: January 12, 2026	By:	/s/ Donald G. Ainscow
	Name:	Donald G. Ainscow
	Title:	Executive Vice President, General Counsel and Secretary

3